Top

Published in:

01-02-2014 | Research Article

Genetic polymorphisms of XRCC3 Thr241Met (C18067T, rs861539) and bladder cancer risk: a meta-analysis of 18 research studies

Authors: Qingtong Ma, Yumei Zhao, Shoufeng Wang, Xiaoyan Zhang, Jinling Zhang, Mei Du, Liang Li, Yun Zhang

Published in: Tumor Biology | Issue 2/2014

Abstract

The relationship of bladder cancer with the presence of X-ray cross-complementing group 3(XRCC3) genetic polymorphismThr241Met has been reported with inconsistent results. The objective of this study was to quantitatively evaluate the association between this polymorphism and bladder cancer susceptibility. A comprehensive research was conducted through PubMed, Medline, Embase, and Web of Science databases up to Aug. 20, 2013. Pooled odds ratio and 95 % confidence interval were calculated using a fixed or random effects model. Statistical analysis was performed with Stata 12.0 software. Of the 18 case–control studies selected for this meta-analysis, a total of 5,667 bladder cancer cases and 7,609 controls were included. The combined results based on all studies suggested that XRCC3 Thr241Met was associated with bladder cancer risk under homozygote and recessive models. When stratifying for ethnicity, significant association was found in Caucasians under homozygote and recessive models. This meta-analysis suggests that XRCC3 Thr241Met polymorphism is a risk factor for bladder cancer risk. However, further well-designed studies are required to confirm our findings.

Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRef

Cohen SM, Shirai T, Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl. 2000;205:105–15.PubMedCrossRef

Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516–7.PubMedCrossRef

Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair, and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef

Bishop DK, Ear U, Bhattacharyya A, et al. XRCC3 is required for assembly of Rad51 complexes in vivo. J Biol Chem. 1998;273:21482–8.PubMedCrossRef

Aka P, Mateuca R, Buchet JP, Thierens H, Kirsch-Volders M. Are genetic polymorphisms in OGG1, XRCC1 and XRCC3 genes predictive for the DNA strand break repair phenotype and genotoxicity in workers exposed to low dose ionizing radiations? Mutat Res. 2004;556:169–81.PubMedCrossRef

Angelini S, Kumar R, Carbone F, Maffei F, Forti GC, Violante FS, et al. Micronuclei in humans induced by exposure to low level of ionizing radiation: influence of polymorphisms in DNA repair genes. Mutat Res. 2005;570:105–17.PubMedCrossRef

Davey SG, Egger M. Meta-analyses of randomized controlled trials. Lancet. 1997;350:1182.

Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef

10.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

11.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

12.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef

13.

Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef

14.

Matullo G, Guarrera S, Carturan S, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.PubMedCrossRef

15.

Stern MC, Umbach DM, Lunn RM, et al. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:939–43.PubMed

16.

Shen M, Hung RJ, Brennan P, et al. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case–control study in northern Italy. Cancer Epidemiol Biomarkers Prev. 2003;12:1234–40.PubMed

17.

Matullo G, Guarrera S, Sacerdote C, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case–control study. Cancer Epidemiol Biomarkers Prev. 2005;14:2569–78.PubMedCrossRef

18.

Broberg K, Björk J, Paulsson K, et al. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.PubMedCrossRef

19.

Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006;27:997–1007.PubMedCrossRef

20.

Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464–79.PubMedCentralPubMedCrossRef

21.

Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28:1788–93.PubMedCrossRef

22.

Hao G, Zhang Y, Zhang W, et al. Relationship between XRCC3 gene polymorphism and bladder cancer in the Han population. J Shandong U. 2008;46:612–5.

23.

Andrew AS, Karagas MR, Nelson HH, et al. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered. 2008;65:105–18.PubMedCrossRef

24.

Fontana L, Bosviel R, Delort L, et al. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res. 2008;28:1853–6.PubMed

25.

Andrew AS, Mason RA, Kelsey KT, et al. DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk. Toxicol Lett. 2009;187:10–4.PubMedCentralPubMedCrossRef

26.

Yang Q, Chen K, Han Q. Studies on polymorphisms of XRCC1, XRCC3 and bladder cancer risk. Chin J Misdiagn. 2009;9:8393–4.

27.

Narter KF, Ergen A, Agaçhan B, et al. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res. 2009;29:1389–93.PubMed

28.

Gangwar R, Ahirwar D, Mandhani A, et al. Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population? Mutat Res. 2009;680:56–63.PubMedCrossRef

29.

Mittal RD, Gangwar R, Mandal RK, Srivastava P, Ahirwar DK. Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer. Mol Biol Rep. 2012;39(2):1667–75.PubMedCrossRef

30.

Zhu X, Zhong Z, Zhang X, Zhao X, Xu R, Ren W, et al. DNA repair gene XRCC3 T241m polymorphism and bladder cancer risk in a Chinese population. Genet Test Mol Biomarkers. 2012;16(6):640–3.PubMedCrossRef

31.

Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20:439–44.PubMedCrossRef

32.

Ioannidis JP, Boffetta P, Little J, O’Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120–32.PubMedCrossRef

Title: Genetic polymorphisms of XRCC3 Thr241Met (C18067T, rs861539) and bladder cancer risk: a meta-analysis of 18 research studies
Authors: Qingtong Ma
Yumei Zhao
Shoufeng Wang
Xiaoyan Zhang
Jinling Zhang
Mei Du
Liang Li
Yun Zhang
Publication date: 01-02-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1203-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Association between SOD2 C47T polymorphism and lung cancer susceptibility: a meta-analysis

The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis

Quantitative assessment of the association between XRCC3 C18607T polymorphism and glioma risk

miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway

Smoking and hOGG1 Ser326Cys polymorphism contribute to lung cancer risk: evidence from a meta-analysis

miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer